Cornish J W, Maany I, Fudala P J, Ehrman R N, Robbins S J, O'Brien C P
Treatment Research Center, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104-6178, USA.
Drug Alcohol Depend. 2001 Jan 1;61(2):183-9. doi: 10.1016/s0376-8716(00)00140-x.
Eighty cocaine-dependent individuals enrolled in outpatient treatment took part in a randomized, double-blind, placebo-controlled trial of ritanserin, a 5-HT(2) antagonist, as an adjunct therapy. Participants attended an outpatient day hospital therapy program each day and received tablets containing placebo or 10 mg ritanserin for a 4-week period. Primary outcome measures included retention in treatment, urine drug tests, and self-reports of craving. Secondary outcome measures were depression scores on the Beck and Hamilton inventories, negative mood as measured by the Profile of Mood States, and life functioning as measured by the Addiction Severity Index. Although participants showed improvement over the 4 weeks, there were no group differences on any of the measures. These results fail to support the use of ritanserin as a complement to outpatient psychosocial therapy for cocaine dependence.
80名参加门诊治疗的可卡因依赖者参与了一项随机、双盲、安慰剂对照试验，该试验将5-羟色胺（2）拮抗剂利坦色林作为辅助疗法。参与者每天参加门诊日间医院治疗项目，并在4周内服用含安慰剂或10毫克利坦色林的药片。主要结局指标包括治疗保留率、尿液药物检测以及对可卡因渴望的自我报告。次要结局指标为贝克和汉密尔顿量表的抑郁评分、情绪状态剖面图测量的负面情绪以及成瘾严重程度指数测量的生活功能。尽管参与者在4周内有所改善，但在任何指标上两组均无差异。这些结果不支持将利坦色林用作可卡因依赖门诊心理社会治疗的补充疗法。
